TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant

TH17 在心肺移植中对 V 型胶原的自身免疫

基本信息

项目摘要

Chronic rejection is the leading cause of death in organ transplant recipients. The co-PIs have discovered a novel link between T-helper type 17 (TH17) responses to the alpha-1 chain of type V collagen [alpha-1 (V)], a component of normal extracellular matrix (ECM) and the process of chronic rejection, known as obliterative bronchiolitis in lung transplants recipients. Recent data show a similar link of col(V) autoimmunity to coronary atherosclerotic disease (CAD) and cardiac allograft vasculopathy (CAV). We propose that disordered ECM deposition seen in small airways of lung during OB, and the vessels of CAD and CAV are manifestations of the same final common pathway in which abnormal expression and immune recognition of alpha-1 (V) play a central role. This program project tests the hypothesis that ECM remodeling resulting from rejection, ischemia reperfusion injury or atherosclerosis results in a "pro-inflammatory" matrix due to overexpression of alpha-1 (V) and associated col(V) TH17-specific CD4+ T cell and B cell responses. Project 1 (Greenspan) will seek to understand the structural bias of a "pro-inflammatory matrix", using targeted transgenic or knockout approaches in mice, resulting in lungs or hearts either overexpressing alpha-1 (V) or deficient in alpha-2(V). Project 2 (Burlingham) will examine the in vivo functions of CD4+ T cells that recognize col(V) in the context of MHC class II. Since collagen binding receptors may impact immune recognition and activation, we will test the importance of collagen receptors, LAIR1 and DDR1, on leukocytes entering a normal or disorded ECM in biasing epitope spreading into a THI7 pathway. Project 3 (Wilkes) will test the hypothesis that B cells producing pathogenic anti-col(V)-specific antibodies have a role in the pathogeneis of lung transplant rejection, and that their synthesis is entirely depend on TH17 and monocytes/macrophages within a disordered matrix. This team of investigators has been highly successful in identifying the central role of col(V) in OB, CAD, and CAV. If the current proposal succeeds, the investigators will have developed tools for the field to advance in dissecting TH17 driven responses to a common tissue antigen that impacts significantly lung and heart transplants, as well as atherosclerosis.
慢性排斥反应是器官移植受者死亡的主要原因。研究人员发现,辅助t - 17型(TH17)对V型胶原α -1链(正常细胞外基质(ECM)的一种成分)的反应与肺移植受者慢性排斥反应(即闭塞性细支气管炎)之间存在新的联系。最近的数据显示,col(V)自身免疫与冠状动脉粥样硬化疾病(CAD)和心脏异体移植血管病变(CAV)之间存在类似的联系。我们认为,OB期间肺小气道中的ECM沉积紊乱,以及CAD和CAV的血管是相同的最终共同途径的表现,其中α -1 (V)的异常表达和免疫识别发挥了核心作用。该项目验证了由排斥反应、缺血再灌注损伤或动脉粥样硬化引起的ECM重塑由于α -1 (V)和相关的col(V) th17特异性CD4+ T细胞和B细胞反应的过度表达而导致“促炎”基质的假设。项目1 (Greenspan)将寻求理解“促炎基质”的结构偏差,在小鼠中使用靶向转基因或敲除方法,导致肺或心脏过度表达α -1 (V)或α -2(V)缺乏。项目2 (Burlingham)将研究在MHC II类背景下识别col(V)的CD4+ T细胞的体内功能。由于胶原结合受体可能影响免疫识别和激活,我们将测试胶原受体LAIR1和DDR1在白细胞进入正常或紊乱的ECM中偏向表位扩散到THI7途径中的重要性。Project 3 (Wilkes)将验证产生致病性抗col(V)特异性抗体的B细胞在肺移植排斥的发病机制中发挥作用的假设,并且它们的合成完全依赖于TH17和无序基质中的单核/巨噬细胞。这组研究人员已经非常成功地确定了col(V)在OB、CAD和CAV中的核心作用。如果目前的提议获得成功,研究人员将开发出工具,推动该领域深入研究TH17驱动的对一种常见组织抗原的反应,这种抗原对肺和心脏移植以及动脉粥样硬化有显著影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David S Wilkes其他文献

A 46-Year-Old Man With Excruciating Shoulder Pain
  • DOI:
    10.1378/chest.127.3.1039
  • 发表时间:
    2005-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Eric J Olafsson;Tallal Zeni;David S Wilkes
  • 通讯作者:
    David S Wilkes

David S Wilkes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David S Wilkes', 18)}}的其他基金

TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8713903
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
IL-17A and anti-col (V) humoral immunity in lung allograft rejection
IL-17A 和抗 col (V) 体液免疫在肺同种异体移植排斥反应中的作用
  • 批准号:
    7810371
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8136215
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7810374
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8317659
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
Renovation of the Wells Research Center for a Pediatric Phenotyping Core
威尔斯研究中心儿科表型分析核心的改造
  • 批准号:
    7935901
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8523761
  • 财政年份:
    2010
  • 资助金额:
    $ 160.71万
  • 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
  • 批准号:
    7694656
  • 财政年份:
    2009
  • 资助金额:
    $ 160.71万
  • 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
  • 批准号:
    8065435
  • 财政年份:
    2009
  • 资助金额:
    $ 160.71万
  • 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
  • 批准号:
    8261696
  • 财政年份:
    2009
  • 资助金额:
    $ 160.71万
  • 项目类别:

相似海外基金

Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunity
识别 1 型糖尿病和自身免疫性疾病中的免疫调节肠道细菌
  • 批准号:
    10467123
  • 财政年份:
    2022
  • 资助金额:
    $ 160.71万
  • 项目类别:
Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunity
识别 1 型糖尿病和自身免疫性疾病中的免疫调节肠道细菌
  • 批准号:
    10613570
  • 财政年份:
    2022
  • 资助金额:
    $ 160.71万
  • 项目类别:
Enhancement of autoimmunity in type 1 diabetes by gluten
麸质增强 1 型糖尿病的自身免疫能力
  • 批准号:
    10390844
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Enhancement of autoimmunity in type 1 diabetes by gluten
麸质增强 1 型糖尿病的自身免疫能力
  • 批准号:
    10490911
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes
富马酸二甲酯用于靶向 1 型糖尿病自身免疫的用途
  • 批准号:
    10354282
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Role of Small Extracellular Vesicles in Beta Cell Failure and Autoimmunity in Type 1 Diabetes Mellitus
小细胞外囊泡在 1 型糖尿病 β 细胞衰竭和自身免疫中的作用
  • 批准号:
    10455673
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Enhancement of autoimmunity in type 1 diabetes by gluten
麸质增强 1 型糖尿病的自身免疫能力
  • 批准号:
    10680525
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Role of Small Extracellular Vesicles in Beta Cell Failure and Autoimmunity in Type 1 Diabetes Mellitus
小细胞外囊泡在 1 型糖尿病 β 细胞衰竭和自身免疫中的作用
  • 批准号:
    10276399
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes
富马酸二甲酯用于靶向 1 型糖尿病自身免疫的用途
  • 批准号:
    10495266
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
Role of Small Extracellular Vesicles in Beta Cell Failure and Autoimmunity in Type 1 Diabetes Mellitus
小细胞外囊泡在 1 型糖尿病 β 细胞衰竭和自身免疫中的作用
  • 批准号:
    10673047
  • 财政年份:
    2021
  • 资助金额:
    $ 160.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了